HM04650 | CRLF3 | thymus | MESH:D011471 | Prostatic Neoplasms | prostate |
HM04650 | CRLF3 | thymus | MESH:D007333 | Insulin Resistance | |
HM04650 | CRLF3 | thymus | MESH:D002278 | Carcinoma in Situ | |
HM04650 | CRLF3 | thymus | MESH:D002278 | Carcinoma in Situ | |
HM04650 | CRLF3 | thymus | MESH:D014591 | Uterine Diseases | uterus |
HM04650 | CRLF3 | thymus | MESH:D014591 | Uterine Diseases | placenta |
HM04650 | CRLF3 | thymus | MESH:D014591 | Uterine Diseases | cervix |
HM04650 | CRLF3 | thymus | MESH:D009421 | Nervous System Malformations | |
HM04650 | CRLF3 | thymus | MESH:D011629 | Puberty, Precocious | |
HM04650 | CRLF3 | thymus | MESH:D011297 | Prenatal Exposure Delayed Effects | |
HM04650 | CRLF3 | thymus | MESH:D010049 | Ovarian Diseases | ovary |
HM04650 | CRLF3 | thymus | MESH:D019966 | Substance-Related Disorders | |
HM04650 | CRLF3 | thymus | MESH:D001862 | Bone Resorption | |
HM04650 | CRLF3 | thymus | MESH:D007249 | Inflammation | |
HM04650 | CRLF3 | thymus | MESH:D001943 | Breast Neoplasms | breast |